Recurrent Clostridioides difficile infection: Recognition, management, prevention

被引:18
作者
Tsigrelis, Constantine [1 ,2 ]
机构
[1] Cleveland Clin, Dept Infect Dis, G21,9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
关键词
FECAL MICROBIOTA TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE EPIDEMIOLOGY; INTESTINAL MICROBIOME; DISEASES SOCIETY; VANCOMYCIN; BEZLOTOXUMAB; UPDATE; ADULTS; FIDAXOMICIN;
D O I
10.3949/ccjm.87gr.20001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clostridioides difficile infection (CDI) is the most common cause of diarrhea in hospitalized patients and results in substantial morbidity, mortality, and costs. Its clinical management, primarily with antibiotics, is often complicated by recurrent episodes. These recurrent CDI episodes are thought to be caused by antibiotic disruption of colonic microbiota and usually occur within 4 weeks of completing antibiotic therapy. The risk of recurrent CDI increases after the first episode, creating a need for management strategies to diagnose, treat, and prevent these complications.
引用
收藏
页码:347 / 359
页数:13
相关论文
共 50 条
  • [21] Recurrence of Clostridioides difficile infection and mortality in older inpatients
    Remelli, Francesca
    Mattioli, Irene
    Govoni, Benedetta
    Zurlo, Amedeo
    De Giorgio, Roberto
    Volpato, Stefano
    Cultrera, Rosario
    EUROPEAN GERIATRIC MEDICINE, 2024, 15 (03) : 743 - 751
  • [22] Risk factors for development of initial Clostridioides difficile infection
    Wagner, Jamie L.
    Stover, Kayla R.
    Bell, Allison M.
    Barber, Katie E.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 18 - 22
  • [23] Update on Treatment of Clostridioides difficile Infection
    Cho, Janice M.
    Pardi, Darrell S.
    Khanna, Sahil
    MAYO CLINIC PROCEEDINGS, 2020, 95 (04) : 758 - 769
  • [24] A Review of Therapies for Clostridioides difficile Infection
    Morado, Faiza
    Nanda, Neha
    ANTIBIOTICS-BASEL, 2025, 14 (01):
  • [25] The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021
    Hyte, Melanie L.
    Arphai, Lee J.
    Vaughn, Charles J.
    Durham, Spencer H.
    ANTIBIOTICS-BASEL, 2022, 11 (09):
  • [26] Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients
    Askar, Sally F.
    Kenney, Rachel M.
    Tariq, Zain
    Conner, Ruth
    Williams, Jonathan
    Ramesh, Mayur
    Alangaden, George J.
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (03) : 584 - 587
  • [27] Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection
    Buehrle, Deanna
    Clancy, Cornelius J.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (12) : 2227 - 2229
  • [28] Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules
    Reigadas, E.
    Bouza, E.
    Olmedo, M.
    Vazquez-Cuesta, S.
    Villar-Gomara, L.
    Alcala, L.
    Marin, M.
    Rodriguez-Fernandez, S.
    Valerio, M.
    Munoz, P.
    JOURNAL OF HOSPITAL INFECTION, 2020, 105 (02) : 319 - 324
  • [29] A review of fecal microbiota, live-js']jslm for the prevention of recurrent Clostridioides difficile infection
    Hunt, Aaron
    Drwiega, Emily
    Wang, Yifan
    Danziger, Larry
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024, 81 (15) : e402 - e411
  • [30] Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
    Berry, Parul
    Khanna, Sahil
    BIODRUGS, 2023, 37 (06) : 757 - 773